S2 Episode 1: Psoriatic Arthritis and Disease Activity Measures S2 Episode 1: Psoriatic Arthritis and Disease Activity Measures
Drs Stanley Cohen and Alexis Ogdie-Beatty discuss minimal disease activity and the disease activity measures used in clinical trials as well as practice in treating psoriatic arthritis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news
Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Novel PsA Treatment Choice Algorithm Uses T-Cell Behavior Novel PsA Treatment Choice Algorithm Uses T-Cell Behavior
A novel treatment algorithm for psoriatic arthritis (PsA) is being developed to provide more precise biologic choices.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
TNF Inhibitor Dose Adaptation in PsA and axSpA (TAPAS) TNF Inhibitor Dose Adaptation in PsA and axSpA (TAPAS)
When it comes to TNF inhibitor treatment in the management of psoriatic arthritis and axial spondyloarthritis, what is the optimal dose?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Cannabidiol for Hand Osteoarthritis and Psoriatic Arthritis Cannabidiol for Hand Osteoarthritis and Psoriatic Arthritis
This study found no significant benefit of cannabidiol over placebo for pain intensity in patients with hand osteoarthritis and psoriatic arthritis.Pain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Treat-to-Target With Tapering Proves Effective in PsA, AxSpA Treat-to-Target With Tapering Proves Effective in PsA, AxSpA
A trial showed for the first time that disease activity-guided, treat-to-target tapering strategies in both psoriatic arthritis and axial spondyloarthritis are noninferior to those without tapering.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 28, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease
The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 17, 2022 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
Bimekizumab Calms Psoriatic Arthritis in Phase 3'BE' Trials Bimekizumab Calms Psoriatic Arthritis in Phase 3'BE' Trials
The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic disease-modifying antirheumatic drug in two trials.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Can Psoriasis Lead to Psoriatic Arthritis?
Title: Can Psoriasis Lead to Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 6/14/2022 12:00:00 AMLast Editorial Review: 6/14/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 14, 2022 Category: Rheumatology Source Type: news
Are Psoriasis and Psoriatic Arthritis the Same?
Title: Are Psoriasis and Psoriatic Arthritis the Same?Category: Diseases and ConditionsCreated: 6/14/2022 12:00:00 AMLast Editorial Review: 6/14/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 14, 2022 Category: Rheumatology Source Type: news
What Can Trigger Psoriatic Arthritis?
Title: What Can Trigger Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 6/14/2022 12:00:00 AMLast Editorial Review: 6/14/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 14, 2022 Category: Rheumatology Source Type: news
What Does Psoriatic Arthritis Joint Pain Feel Like?
Title: What Does Psoriatic Arthritis Joint Pain Feel Like?Category: Diseases and ConditionsCreated: 6/14/2022 12:00:00 AMLast Editorial Review: 6/14/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 14, 2022 Category: Rheumatology Source Type: news
Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritis
(MedPage Today) -- COPENHAGEN -- In a phase II study reported here, a small-molecule drug engineered to inhibit interleukin (IL)-17A appeared effective and safe among patients with psoriatic arthritis (PsA).
Half of patients receiving either... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 4, 2022 Category: Dermatology Source Type: news
Sex and the (Not Quite) Single Arthritis Patient
(MedPage Today) -- COPENHAGEN -- Half of patients with rheumatoid arthritis (RA) and 30% of those with psoriatic arthritis (PsA) reported substantial problems with sexual function, according to a survey reported here.
Among 27 with RA diagnoses... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 2, 2022 Category: OBGYN Source Type: news
New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
